Highlights
- Omecamtiv mecarbil (OM) demonstrated consistent clinical benefits in reducing cardiovascular death or first heart failure events across the entire age spectrum (18–85 years).
- The treatment effect was particularly robust in patients with severe heart failure, regardless of whether they were under or over 65 years of age.
- Unlike many traditional inotropes, OM showed no significant interaction with age regarding safety outcomes, including blood pressure and heart rate stability.
- In the GALACTIC-HF trial, more than half of the participants (54.5%) were aged 65 or older, providing high-quality evidence for geriatric heart failure management.
Background
Heart failure with reduced ejection fraction (HFrEF) is a progressive condition that disproportionately affects older adults. As the population ages, clinicians face the challenge of managing patients who not only have higher baseline cardiovascular risks but also present with significant comorbidities, such as chronic kidney disease, frailty, and polypharmacy. Older patients are often more susceptible to the adverse effects of conventional heart failure therapies, particularly those that lower blood pressure (e.g., ACE inhibitors, ARBs, ARNIs) or affect heart rate (e.g., beta-blockers).
Omecamtiv mecarbil (OM) represents a novel class of therapeutic agents known as selective cardiac myosin activators. Unlike traditional inotropic agents that increase intracellular calcium—often leading to increased myocardial oxygen demand and arrhythmias—OM directly binds to cardiac myosin. This mechanism increases the number of myosin heads that can bind to the actin filament during systole, thereby enhancing myocardial contractility and stroke volume without increasing calcium transients or altering blood pressure and heart rate. Given this unique pharmacological profile, OM has been hypothesized to be particularly well-tolerated and effective in the elderly, a population that frequently struggles with hemodynamic instability.
Key Content
The GALACTIC-HF Trial: Design and Age-Specific Rationale
The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial was a phase 3, randomized, double-blind, placebo-controlled study that enrolled 8,232 patients with symptomatic HFrEF (LVEF ≤35%). Patients were randomized to receive either omecamtiv mecarbil (dose-titrated to 25 mg, 37.5 mg, or 50 mg twice daily based on plasma levels) or a matching placebo. A key feature of this trial was its broad inclusion criteria, which allowed for a robust representation of older individuals, with a maximum age limit of 85 years.
Demographic Breakdown and Event Rates
The sub-analysis recently published by Lu et al. (2025) categorized the cohort into two primary groups: <65 years (n=3,744) and ≥65 years (n=4,488). The mean age of the total population was 64.5 ± 11.4 years. As expected, older patients (≥65) had a higher burden of comorbidities and a higher incidence of the primary outcome (cardiovascular death or first heart failure event). Specifically, the event rate was 28.8 per 100 patient-years in the ≥65 group compared to 21.4 per 100 patient-years in the <65 group, reinforcing the high-risk nature of the geriatric heart failure population.
Efficacy Across the Age Spectrum
In the overall trial population, omecamtiv mecarbil reduced the risk of the primary composite endpoint (Hazard Ratio [HR]: 0.92; 95% CI: 0.86–0.99; P = 0.03). When analyzed by age group, the treatment effect remained remarkably consistent. For patients <65 years, the HR was 0.93 (95% CI: 0.84–1.03), and for those ≥65 years, the HR was 0.91 (95% CI: 0.84–0.99). The P-interaction for age as a categorical variable was 0.76, indicating no difference in efficacy between younger and older cohorts.
Furthermore, when age was modeled as a continuous variable, the benefit of OM remained stable even after adjusting for known treatment modifiers such as baseline Left Ventricular Ejection Fraction (LVEF) and atrial fibrillation status (P-interaction = 0.19).
Superior Benefit in Severe Heart Failure
One of the most clinically significant findings was the enhanced efficacy of OM in the “severe heart failure” subgroup. This subgroup was defined by LVEF ≤30%, NYHA functional class III or IV, and a heart failure hospitalization within the previous 6 months. In these high-vulnerability patients, omecamtiv mecarbil demonstrated a more pronounced risk reduction:
- Patients <65 years: HR 0.77 (95% CI: 0.64–0.92)
- Patients ≥65 years: HR 0.83 (95% CI: 0.71–0.97)
The consistency of this benefit (P-interaction = 0.47) suggests that even in the most advanced stages of the disease, age does not attenuate the contractile advantages provided by myosin activation.
Safety and Tolerability Profile
Safety is a paramount concern in geriatric medicine due to reduced physiological reserve. In GALACTIC-HF, the safety profile of omecamtiv mecarbil was consistent across all age groups. There were no significant differences in the rates of serious adverse events, including myocardial infarction or ventricular arrhythmias, between the treatment and placebo arms in older patients. Notably, the “hemodynamic neutrality” of the drug—meaning it did not cause significant drops in blood pressure—was maintained in the ≥65 group, which is vital for patients often dealing with orthostatic hypotension or renal impairment.
Expert Commentary
The findings from this GALACTIC-HF sub-analysis provide a reassuring evidence base for the use of omecamtiv mecarbil in an aging population. Historically, older patients have been underrepresented in heart failure trials, or have been shown to derive less benefit from certain interventions due to the competing risk of non-cardiovascular death. However, OM appears to bypass these limitations by targeting the core mechanical deficit of HFrEF—impaired systolic function—without the systemic side effects that plague calcium-sensitizing or sympathomimetic agents.
The mechanistic biological rationale is particularly compelling for the elderly. Aging is associated with changes in the myocardial structure, including increased fibrosis and altered myosin isoform expression. By directly facilitating the actin-myosin cross-bridge formation, OM improves the duration of ejection without requiring the metabolic cost of increased heart rate. For a clinician, this means OM can be safely added to a regimen of “quadruple therapy” (Beta-blockers, MRA, SGLT2i, and ARNI) even if the patient’s blood pressure is borderline low, which is a common clinical scenario in those over 75.
One controversy remains: despite the positive results in the primary endpoint, the reduction in cardiovascular death alone did not reach statistical significance in the overall trial. This suggests that while OM is excellent at reducing hospitalizations and improving the clinical course of heart failure, it may not be a stand-alone solution for mortality in the most heterogeneous older populations. Clinicians should view OM as a specialized tool for symptom and event management, particularly in patients with low LVEF who remain symptomatic despite standard medical therapy.
Conclusion
The GALACTIC-HF trial confirms that omecamtiv mecarbil is a safe and effective therapeutic option for HFrEF across the age spectrum. Its benefits are notably preserved, and even enhanced, in patients with severe heart failure. As the first-in-class cardiac myosin activator, OM offers a unique pathway for improving myocardial function that is well-suited for the complex hemodynamic and physiological needs of older patients. Future research should focus on the long-term impact of OM on frailty markers and quality of life in the very elderly (those >85 years), who were less represented in the current data.
References
- Lu H, Claggett BL, Felker GM, McMurray JJV, Teerlink JR, Inciardi RM, Metra M, Heitner SB, Diaz R, Malik F, Vaduganathan M, Solomon SD. Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial. JACC Heart Fail. 2025 Oct 22:102703. doi: 10.1016/j.jchf.2025.102703. PMID: 41123512.
- Teerlink JR, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021;384(2):105-116. PMID: 33185360.